메뉴 건너뛰기




Volumn 48, Issue 9, 2016, Pages 995-1005

From current status to optimization of HCV treatment: Recommendations from an expert panel

(26)  Craxì, Antonio r   Perno, Carlo Federico s   Viganò, Mauro a   Ceccherini Silberstein, Francesca s   Petta, Salvatore r   Aghemo, Alessio a   Alberti, Alfredo b   Andreone, Pietro c   Andreoni, Massimo c   Bonora, Stefano d   Brunetto, Maurizia Rossana e   Bruno, Savino f   Caporaso, Nicola g   Chirianni, Antonio h   Ciancio, Alessia d   Degasperi, Elisabetta a   Di Perri, Giovanni d   Fagiuoli, Stefano i   Ferrari, Carlo j   Gaeta, Giovanni Battista k   more..


Author keywords

Antiviral therapy; Cirrhosis; Direct acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; ALPHA INTERFERON; RIBAVIRIN;

EID: 84986601943     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.06.004     Document Type: Article
Times cited : (15)

References (97)
  • 2
    • 84945534889 scopus 로고    scopus 로고
    • Extrahepatic morbidity and mortality of chronic hepatitis C
    • [2] Negro, F., Forton, D., Craxì, A., et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
    • (2015) Gastroenterology , vol.149 , pp. 1345-1360
    • Negro, F.1    Forton, D.2    Craxì, A.3
  • 5
    • 34250679750 scopus 로고    scopus 로고
    • Epidemiology of hepatitis C virus infection
    • [5] Alter, M.J., Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 13 (2007), 2436–2441.
    • (2007) World Journal of Gastroenterology , vol.13 , pp. 2436-2441
    • Alter, M.J.1
  • 6
    • 84921060015 scopus 로고    scopus 로고
    • Global distribution and prevalence of hepatitis C virus genotypes
    • [6] Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
    • (2015) Hepatology , vol.61 , pp. 77-87
    • Messina, J.P.1    Humphreys, I.2    Flaxman, A.3
  • 7
    • 84939653819 scopus 로고    scopus 로고
    • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
    • [7] AASLD/IDSA Guidance Panel, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
    • (2015) Hepatology , vol.62 , pp. 932-954
    • AASLD/IDSA Guidance Panel1
  • 8
    • 84931560807 scopus 로고    scopus 로고
    • Recommendations on treatment of hepatitis C 2015
    • [8] EASL, Recommendations on treatment of hepatitis C 2015. Journal of Hepatology 63 (2015), 199–236.
    • (2015) Journal of Hepatology , vol.63 , pp. 199-236
    • EASL1
  • 9
    • 84986582659 scopus 로고    scopus 로고
    • Documento di indirizzo dell'Associazione Italiana per lo Studio del Fegato per l'uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammessi alla rimborsabilità in Italia
    • [accessed February 2016].
    • [9] AISF. Documento di indirizzo dell'Associazione Italiana per lo Studio del Fegato per l'uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammessi alla rimborsabilità in Italia. http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2015.aspx [accessed February 2016].
    • AISF1
  • 10
    • 84942021358 scopus 로고    scopus 로고
    • Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response
    • [10] Simmons, B., Saleem, J., Heath, K., et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clinical Infectious Diseases 61 (2015), 730–740.
    • (2015) Clinical Infectious Diseases , vol.61 , pp. 730-740
    • Simmons, B.1    Saleem, J.2    Heath, K.3
  • 11
    • 84896492970 scopus 로고    scopus 로고
    • Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
    • [11] Hsu, Y.-C., Lin, J.-T., Ho, H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59 (2014), 1293–1302.
    • (2014) Hepatology , vol.59 , pp. 1293-1302
    • Hsu, Y.-C.1    Lin, J.-T.2    Ho, H.J.3
  • 12
    • 63349097919 scopus 로고    scopus 로고
    • Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    • [12] Arase, Y., Suzuki, F., Suzuki, Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49 (2009), 739–744.
    • (2009) Hepatology , vol.49 , pp. 739-744
    • Arase, Y.1    Suzuki, F.2    Suzuki, Y.3
  • 13
    • 84922360592 scopus 로고    scopus 로고
    • Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection
    • [13] Hsu, Y.C., Ho, H.J., Huang, Y.T., et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64 (2015), 495–503.
    • (2015) Gut , vol.64 , pp. 495-503
    • Hsu, Y.C.1    Ho, H.J.2    Huang, Y.T.3
  • 14
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • [14] van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3
  • 15
    • 79957497436 scopus 로고    scopus 로고
    • A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C
    • [15] Backus, L.I., Boothroyd, D.B., Phillips, B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clinical Gastroenterology and Hepatology 9 (2011), 509–516.
    • (2011) Clinical Gastroenterology and Hepatology , vol.9 , pp. 509-516
    • Backus, L.I.1    Boothroyd, D.B.2    Phillips, B.R.3
  • 16
    • 77952704228 scopus 로고    scopus 로고
    • Sustained virologic response prevents the development of esophageal varices in compensated, Child–Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study
    • [16] Bruno, S., Crosignani, A., Facciotto, C., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child–Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51 (2010), 2069–2076.
    • (2010) Hepatology , vol.51 , pp. 2069-2076
    • Bruno, S.1    Crosignani, A.2    Facciotto, C.3
  • 17
    • 33947360829 scopus 로고    scopus 로고
    • Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    • [17] Bruno, S., Stroffolini, T., Colombo, M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
    • (2007) Hepatology , vol.45 , pp. 579-587
    • Bruno, S.1    Stroffolini, T.2    Colombo, M.3
  • 18
    • 80052441244 scopus 로고    scopus 로고
    • The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
    • [18] D'Ambrosio, R., Aghemo, A., Rumi, M.G., et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antiviral Therapy 16 (2011), 677–684.
    • (2011) Antiviral Therapy , vol.16 , pp. 677-684
    • D'Ambrosio, R.1    Aghemo, A.2    Rumi, M.G.3
  • 19
    • 84864367149 scopus 로고    scopus 로고
    • A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
    • [19] D'Ambrosio, R., Aghemo, A., Rumi, M.G., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56 (2012), 532–543.
    • (2012) Hepatology , vol.56 , pp. 532-543
    • D'Ambrosio, R.1    Aghemo, A.2    Rumi, M.G.3
  • 20
    • 84877795646 scopus 로고    scopus 로고
    • Sustained virological response: a milestone in the treatment of chronic hepatitis C
    • [20] Morisco, F., Granata, R., Stroffolini, T., et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World Journal of Gastroenterology 19 (2013), 2793–2798.
    • (2013) World Journal of Gastroenterology , vol.19 , pp. 2793-2798
    • Morisco, F.1    Granata, R.2    Stroffolini, T.3
  • 21
    • 84952837740 scopus 로고    scopus 로고
    • Is the benefit of treating patients with cirrhosis proven?
    • [21] Bruno, S., Boccaccio, V., Russo, M.L., et al. Is the benefit of treating patients with cirrhosis proven?. Liver International 36 (2016), S21–S27.
    • (2016) Liver International , vol.36 , pp. S21-S27
    • Bruno, S.1    Boccaccio, V.2    Russo, M.L.3
  • 22
    • 84959559169 scopus 로고    scopus 로고
    • All-Oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study
    • [Epub ahead of print]
    • [22] Leroy, V., Angus, P.W., Bronowicki, J.P., et al. All-Oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study. Hepatology, 2016, 10.1002/hep.28473 [Epub ahead of print].
    • (2016) Hepatology
    • Leroy, V.1    Angus, P.W.2    Bronowicki, J.P.3
  • 23
    • 84901036125 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
    • [23] Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New England Journal of Medicine 370 (2014), 1973–1982.
    • (2014) New England Journal of Medicine , vol.370 , pp. 1973-1982
    • Poordad, F.1    Hezode, C.2    Trinh, R.3
  • 24
    • 84933181270 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis
    • [24] Reddy, K.R., Bourlière, M., Sulkowski, M., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
    • (2015) Hepatology , vol.62 , pp. 79-86
    • Reddy, K.R.1    Bourlière, M.2    Sulkowski, M.3
  • 25
    • 84979066379 scopus 로고    scopus 로고
    • Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)
    • [Epub ahead of print]
    • [25] Lawitz, E., Matusow, G., DeJesus, E., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology, 2015, 10.1002/hep.28422 [Epub ahead of print].
    • (2015) Hepatology
    • Lawitz, E.1    Matusow, G.2    DeJesus, E.3
  • 27
    • 77949514845 scopus 로고    scopus 로고
    • Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice
    • [27] Chevaliez, S., Bouvier-Alias, M., Brillet, R., et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE, 4, 2009, e8209.
    • (2009) PLoS ONE , vol.4 , pp. e8209
    • Chevaliez, S.1    Bouvier-Alias, M.2    Brillet, R.3
  • 28
    • 84936817310 scopus 로고    scopus 로고
    • Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents
    • [Epub ahead of print]
    • [28] Ceccherini Silberstein, F., Di Maio, V.C., Aragri, M., et al. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology, 2015, 10.1002/hep.27895 [Epub ahead of print].
    • (2015) Hepatology
    • Ceccherini Silberstein, F.1    Di Maio, V.C.2    Aragri, M.3
  • 29
    • 69949182408 scopus 로고    scopus 로고
    • Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
    • [29] Bochud, P.Y., Cai, T., Overbeck, K., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology 51 (2009), 655–666.
    • (2009) Journal of Hepatology , vol.51 , pp. 655-666
    • Bochud, P.Y.1    Cai, T.2    Overbeck, K.3
  • 31
    • 84943558459 scopus 로고    scopus 로고
    • Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection
    • [31] Foster, G., Pianko, S., Brown, A., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
    • (2015) Gastroenterology , vol.149 , pp. 1462-1470
    • Foster, G.1    Pianko, S.2    Brown, A.3
  • 32
    • 84925364974 scopus 로고    scopus 로고
    • All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
    • [32] Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
    • (2015) Hepatology , vol.61 , pp. 1127-1135
    • Nelson, D.R.1    Cooper, J.N.2    Lalezari, J.P.3
  • 33
    • 84961718490 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
    • [33] Hèzode, C., et al., De Ledinghen, V., Fontaine, H., et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology, 62(Suppl. 1), 2015, 315A.
    • (2015) Hepatology , vol.62 , pp. 315A
    • Hèzode, C.1    De Ledinghen, V.2    Fontaine, H.3
  • 34
    • 84954399628 scopus 로고    scopus 로고
    • The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
    • [34] Sarrazin, C., The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology 64 (2016), 486–504.
    • (2016) Journal of Hepatology , vol.64 , pp. 486-504
    • Sarrazin, C.1
  • 35
    • 84986628244 scopus 로고    scopus 로고
    • Abstract from the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), Berlin 26–28th June
    • [35] Nelson, D.R., Abstract from the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), Berlin 26–28th June. 2015.
    • (2015)
    • Nelson, D.R.1
  • 36
    • 84901044326 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
    • [36] Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New England Journal of Medicine 370 (2014), 1983–1992.
    • (2014) New England Journal of Medicine , vol.370 , pp. 1983-1992
    • Ferenci, P.1    Bernstein, D.2    Lalezari, J.3
  • 37
    • 84904647749 scopus 로고    scopus 로고
    • ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
    • [37] Andreone, P., Colombo, M.G., Enejosa, J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147 (2014), 359–365.
    • (2014) Gastroenterology , vol.147 , pp. 359-365
    • Andreone, P.1    Colombo, M.G.2    Enejosa, J.V.3
  • 38
    • 84991085939 scopus 로고    scopus 로고
    • FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
    • [38] FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm.
  • 39
    • 84900339263 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
    • [39] Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine 370 (2014), 1889–1898.
    • (2014) New England Journal of Medicine , vol.370 , pp. 1889-1898
    • Afdhal, N.1    Zeuzem, S.2    Kwo, P.3
  • 40
    • 84898669547 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    • [40] Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine 370 (2014), 1483–1493.
    • (2014) New England Journal of Medicine , vol.370 , pp. 1483-1493
    • Afdhal, N.1    Reddy, K.R.2    Nelson, D.R.3
  • 41
    • 84900326091 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
    • [41] Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine 370 (2014), 1879–1888.
    • (2014) New England Journal of Medicine , vol.370 , pp. 1879-1888
    • Kowdley, K.V.1    Gordon, S.C.2    Reddy, K.R.3
  • 42
    • 84979953208 scopus 로고    scopus 로고
    • Treatment outcomes with 8, 12 and 24 week regimens of Ledipasvir/Sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational Study
    • [42] Terrault, N., Zeuzem, S., Di Bisceglie, A.M., et al. Treatment outcomes with 8, 12 and 24 week regimens of Ledipasvir/Sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational Study. Hepatology, 62(Suppl. 1), 2015, 256A.
    • (2015) Hepatology , vol.62 , pp. 256A
    • Terrault, N.1    Zeuzem, S.2    Di Bisceglie, A.M.3
  • 43
    • 84892619580 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
    • [43] Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 370 (2014), 211–221.
    • (2014) New England Journal of Medicine , vol.370 , pp. 211-221
    • Sulkowski, M.S.1    Gardiner, D.F.2    Rodriguez-Torres, M.3
  • 44
    • 84936845723 scopus 로고    scopus 로고
    • Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study
    • [44] Poordad, F., Shiff, E.R., Vierling, J.M., et al. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. Journal of Hepatology 62 (2015), S261–S262.
    • (2015) Journal of Hepatology , vol.62 , pp. S261-S262
    • Poordad, F.1    Shiff, E.R.2    Vierling, J.M.3
  • 45
    • 84986588416 scopus 로고    scopus 로고
    • Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of Elbasvir/Grazoprevir (EBR/GZR) against GT1a Infection
    • [45] Jacobson, I.M., Asante-Appiah, E., Wong, P., et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of Elbasvir/Grazoprevir (EBR/GZR) against GT1a Infection. Hepatology, 62, 2015, 1393A.
    • (2015) Hepatology , vol.62 , pp. 1393A
    • Jacobson, I.M.1    Asante-Appiah, E.2    Wong, P.3
  • 46
    • 85002451771 scopus 로고    scopus 로고
    • A phase 3 double-blind placebo-controlled evaluation of Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in naïve and experienced Genotype 1, 2, 4, 5, 6 HCV infected patients with and without cirrhosis: results of the ASTRAL-1 study
    • [46] Feld, J.J., Agarwal, K., Hezode, C., et al. A phase 3 double-blind placebo-controlled evaluation of Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in naïve and experienced Genotype 1, 2, 4, 5, 6 HCV infected patients with and without cirrhosis: results of the ASTRAL-1 study. Hepatology, 62, 2015, 1379A.
    • (2015) Hepatology , vol.62 , pp. 1379A
    • Feld, J.J.1    Agarwal, K.2    Hezode, C.3
  • 47
    • 84952931354 scopus 로고    scopus 로고
    • Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis
    • [47] Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. New England Journal of Medicine 373 (2015), 2618–2628.
    • (2015) New England Journal of Medicine , vol.373 , pp. 2618-2628
    • Curry, M.P.1    O'Leary, J.G.2    Bzowej, N.3
  • 48
    • 84877265572 scopus 로고    scopus 로고
    • HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study
    • [48] Kirk, G.D., Mehta, S.H., Astemborski, J., et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Annals of Internal Medicine 158 (2013), 658–666.
    • (2013) Annals of Internal Medicine , vol.158 , pp. 658-666
    • Kirk, G.D.1    Mehta, S.H.2    Astemborski, J.3
  • 49
    • 84896509055 scopus 로고    scopus 로고
    • Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study
    • [49] Lo Re, V., Kallan, M.J., Tate, J.P., et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals of Internal Medicine 160 (2014), 369–377.
    • (2014) Annals of Internal Medicine , vol.160 , pp. 369-377
    • Lo Re, V.1    Kallan, M.J.2    Tate, J.P.3
  • 50
    • 84913598185 scopus 로고    scopus 로고
    • Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFα receptor subtype 2
    • [50] Pircher, J., Czermak, T., Merkle, M., et al. Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFα receptor subtype 2. PLoS ONE, 9, 2014, e113351.
    • (2014) PLoS ONE , vol.9 , pp. e113351
    • Pircher, J.1    Czermak, T.2    Merkle, M.3
  • 51
    • 84866379288 scopus 로고    scopus 로고
    • All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection
    • [51] Hernando, V., Perez-Cachafeiro, S., Lewden, C., et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. Journal of Hepatology 57 (2012), 743–751.
    • (2012) Journal of Hepatology , vol.57 , pp. 743-751
    • Hernando, V.1    Perez-Cachafeiro, S.2    Lewden, C.3
  • 52
    • 84939824828 scopus 로고    scopus 로고
    • Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1
    • [52] Naggie, S., Cooper, C., Saag, M., et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine 373 (2015), 705–713.
    • (2015) New England Journal of Medicine , vol.373 , pp. 705-713
    • Naggie, S.1    Cooper, C.2    Saag, M.3
  • 53
    • 84925428093 scopus 로고    scopus 로고
    • Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial
    • [53] Sulkowski, M.S., Eron, J.J., Wyles, D., et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 313 (2015), 1223–1231.
    • (2015) JAMA , vol.313 , pp. 1223-1231
    • Sulkowski, M.S.1    Eron, J.J.2    Wyles, D.3
  • 54
    • 84939833091 scopus 로고    scopus 로고
    • Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1
    • [54] Wyles, D.L., Ruane, P.J., Sulkowski, M.S., et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine 373 (2015), 714–725.
    • (2015) New England Journal of Medicine , vol.373 , pp. 714-725
    • Wyles, D.L.1    Ruane, P.J.2    Sulkowski, M.S.3
  • 55
    • 84862572786 scopus 로고    scopus 로고
    • Impact of hepatitis C co-infection on response to antiretroviral treatment
    • [55] Pulido, F., Hill, A., van Delft, Y., et al. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Reviews 14 (2012), 124–131.
    • (2012) AIDS Reviews , vol.14 , pp. 124-131
    • Pulido, F.1    Hill, A.2    van Delft, Y.3
  • 56
    • 58649101395 scopus 로고    scopus 로고
    • Treatment of HBV/HCV coinfection: releasing the enemy within
    • [56] Gordon, S.C., Sherman, K.E., Treatment of HBV/HCV coinfection: releasing the enemy within. Gastroenterology 136 (2009), 393–396.
    • (2009) Gastroenterology , vol.136 , pp. 393-396
    • Gordon, S.C.1    Sherman, K.E.2
  • 57
    • 84984585800 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
    • [57] Liu, C.J., Chuang, W.L., Lee, C.M., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136 (2009), 496–504.
    • (2009) Gastroenterology , vol.136 , pp. 496-504
    • Liu, C.J.1    Chuang, W.L.2    Lee, C.M.3
  • 58
    • 84945917920 scopus 로고    scopus 로고
    • Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection
    • [Epub ahead of print]
    • [58] Takayama, H., Sato, T., Ikeda, F., et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatology Research, 2015, 10.1111/hepr.12578 [Epub ahead of print].
    • (2015) Hepatology Research
    • Takayama, H.1    Sato, T.2    Ikeda, F.3
  • 59
    • 84943328235 scopus 로고    scopus 로고
    • Virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir
    • [59] Collins, J.M., Raphael, K.L., Terry, C., et al. Virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clinical Infectious Diseases 61 (2015), 1304–1306.
    • (2015) Clinical Infectious Diseases , vol.61 , pp. 1304-1306
    • Collins, J.M.1    Raphael, K.L.2    Terry, C.3
  • 60
    • 84919342750 scopus 로고    scopus 로고
    • Extrahepatic manifestations of chronic hepatitis C virus infection
    • [60] Cacoub, P., Gragnani, L., Comarmond, C., et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Digestive and Liver Disease 46:Suppl. 5 (2014), S165–S173.
    • (2014) Digestive and Liver Disease , vol.46 , pp. S165-S173
    • Cacoub, P.1    Gragnani, L.2    Comarmond, C.3
  • 61
    • 33845968066 scopus 로고    scopus 로고
    • For the Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach
    • [61] Zignego, A.L., Ferri, C., Pileri, S.A., et al. For the Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Digestive and Liver Disease 39 (2007), 2–17.
    • (2007) Digestive and Liver Disease , vol.39 , pp. 2-17
    • Zignego, A.L.1    Ferri, C.2    Pileri, S.A.3
  • 62
    • 85014612062 scopus 로고    scopus 로고
    • Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study
    • [Epub ahead of print]
    • [62] Saadoun, D., Thibault, V., Si Ahmed, S.N., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the Rheumatic Diseases, 2015 [Epub ahead of print].
    • (2015) Annals of the Rheumatic Diseases
    • Saadoun, D.1    Thibault, V.2    Si Ahmed, S.N.3
  • 63
    • 84923037678 scopus 로고    scopus 로고
    • Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study
    • [63] Michot, J.M., Canioni, D., Driss, H., et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. American Journal of Hematology 90 (2015), 197–203.
    • (2015) American Journal of Hematology , vol.90 , pp. 197-203
    • Michot, J.M.1    Canioni, D.2    Driss, H.3
  • 64
    • 85020275293 scopus 로고    scopus 로고
    • Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study
    • [Epub ahead of print]
    • [64] Gragnani, L., Piluso, A., Urraro, T., et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Current Drug Targets, 2016 [Epub ahead of print].
    • (2016) Current Drug Targets
    • Gragnani, L.1    Piluso, A.2    Urraro, T.3
  • 65
    • 84938953785 scopus 로고    scopus 로고
    • Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease
    • [65] Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
    • (2015) Gastroenterology , vol.149 , pp. 649-659
    • Charlton, M.1    Everson, G.T.2    Flamm, S.L.3
  • 66
    • 84976260348 scopus 로고    scopus 로고
    • Ledipasvir and Sofosbuvir plus Ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial
    • [Epub ahead of print]
    • [66] Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and Sofosbuvir plus Ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial. Lancet Infectious Diseases, 2016, 10.1016/S1473-3099(16)00052-9 [Epub ahead of print].
    • (2016) Lancet Infectious Diseases
    • Manns, M.1    Samuel, D.2    Gane, E.J.3
  • 67
    • 84962847001 scopus 로고    scopus 로고
    • Cohort study of the impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
    • [in press]
    • [67] Foster, G., Irving, W., Cheung, M.C.M., et al. Cohort study of the impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 2016, 10.1016/j.jhep.2016.01.029 [in press].
    • (2016) Journal of Hepatology
    • Foster, G.1    Irving, W.2    Cheung, M.C.M.3
  • 68
    • 84939255617 scopus 로고    scopus 로고
    • All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience
    • [68] Reddy, R., Lim, J.K., Kuo, A., et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience. Journal of Hepatology, 62, 2015, S193.
    • (2015) Journal of Hepatology , vol.62 , pp. S193
    • Reddy, R.1    Lim, J.K.2    Kuo, A.3
  • 69
    • 84932650978 scopus 로고    scopus 로고
    • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis
    • [69] Saxena, V., Nyberg, L., Pauly, M.P., et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology 62 (2015), 715–725.
    • (2015) Hepatology , vol.62 , pp. 715-725
    • Saxena, V.1    Nyberg, L.2    Pauly, M.P.3
  • 70
    • 84938572955 scopus 로고    scopus 로고
    • Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-salt part A)
    • [70] Jacobson, I.M., Poordad, F., Firpi-Morell, R., et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-salt part A). Journal of Hepatology, 62, 2015, S193.
    • (2015) Journal of Hepatology , vol.62 , pp. S193
    • Jacobson, I.M.1    Poordad, F.2    Firpi-Morell, R.3
  • 71
    • 84922879093 scopus 로고    scopus 로고
    • Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study
    • [71] Curry, M.P., Forns, X., Chung, R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107.
    • (2015) Gastroenterology , vol.148 , pp. 100-107
    • Curry, M.P.1    Forns, X.2    Chung, R.T.3
  • 72
    • 84930578857 scopus 로고    scopus 로고
    • Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients
    • [72] Burgess, S., Partovi, N., Yoshida, E.M., et al. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Annals of Pharmacotherapy 49 (2015), 674–687.
    • (2015) Annals of Pharmacotherapy , vol.49 , pp. 674-687
    • Burgess, S.1    Partovi, N.2    Yoshida, E.M.3
  • 73
    • 85012867206 scopus 로고    scopus 로고
    • Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection
    • [73] Fontana, R.J., Brown, R., Herzer, J., et al. Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection. Journal of Hepatology, 62, 2015, S629.
    • (2015) Journal of Hepatology , vol.62 , pp. S629
    • Fontana, R.J.1    Brown, R.2    Herzer, J.3
  • 74
    • 84928208414 scopus 로고    scopus 로고
    • Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation
    • [74] Forns, X., Charlton, M., Denning, J., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61 (2015), 1485–1494.
    • (2015) Hepatology , vol.61 , pp. 1485-1494
    • Forns, X.1    Charlton, M.2    Denning, J.3
  • 75
    • 84929582082 scopus 로고    scopus 로고
    • Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant
    • [75] Pungpapong, S., Aqel, B., Leise, M., et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61 (2015), 1880–1886.
    • (2015) Hepatology , vol.61 , pp. 1880-1886
    • Pungpapong, S.1    Aqel, B.2    Leise, M.3
  • 76
    • 84919360641 scopus 로고    scopus 로고
    • An interferon-free antiviral regimen for HCV after liver transplantation
    • [76] Kwo, P.Y., Mantry, P.S., Coakley, E.T., et al. An interferon-free antiviral regimen for HCV after liver transplantation. New England Journal of Medicine 371 (2014), 2375–2382.
    • (2014) New England Journal of Medicine , vol.371 , pp. 2375-2382
    • Kwo, P.Y.1    Mantry, P.S.2    Coakley, E.T.3
  • 77
    • 84922879130 scopus 로고    scopus 로고
    • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation
    • [77] Charlton, M., Gane, E., Manns, M.P., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
    • (2015) Gastroenterology , vol.148 , pp. 108-117
    • Charlton, M.1    Gane, E.2    Manns, M.P.3
  • 78
    • 84920941109 scopus 로고    scopus 로고
    • Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late
    • [78] Pellicelli, A.M., Montalbano, M., Lionetti, R., et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease 46 (2014), 923–927.
    • (2014) Digestive and Liver Disease , vol.46 , pp. 923-927
    • Pellicelli, A.M.1    Montalbano, M.2    Lionetti, R.3
  • 79
    • 84939271310 scopus 로고    scopus 로고
    • The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/− RBV
    • [79] Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/− RBV. Journal of Hepatology, 62, 2015, S620.
    • (2015) Journal of Hepatology , vol.62 , pp. S620
    • Sarrazin, C.1    Dvory-Sobol, H.2    Svarovskaia, E.S.3
  • 80
    • 84986583915 scopus 로고    scopus 로고
    • Baseline HCV NS5A resistance-associated variants do not impact SVR12 rates in non-cirrhotic and post-liver transplant patients with genotype 1 infection treated with daclatasvir and sofosbuvir with or without ribavirin for 12 weeks: an integrated analysis
    • [80] McPhee, F., Hernandez, D., Zhou, N., et al. Baseline HCV NS5A resistance-associated variants do not impact SVR12 rates in non-cirrhotic and post-liver transplant patients with genotype 1 infection treated with daclatasvir and sofosbuvir with or without ribavirin for 12 weeks: an integrated analysis. Hepatology, 62(Suppl. 1), 2015, 560A.
    • (2015) Hepatology , vol.62 , pp. 560A
    • McPhee, F.1    Hernandez, D.2    Zhou, N.3
  • 81
    • 84941917709 scopus 로고    scopus 로고
    • Hepatitis C virus drug resistance – associated substitutions: state of the art summary
    • [81] Lontok, E., Harrington, P., Howe, A., et al. Hepatitis C virus drug resistance – associated substitutions: state of the art summary. Hepatology 62 (2015), 1623–1632.
    • (2015) Hepatology , vol.62 , pp. 1623-1632
    • Lontok, E.1    Harrington, P.2    Howe, A.3
  • 82
    • 84986576843 scopus 로고    scopus 로고
    • Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for retreatment
    • [Abstract AISF 2016]
    • [82] Di Maio, V.C., Cento, V., Di Paolo, D., et al. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for retreatment. DLD, 48(Suppl. 2), 2016, 10.106/j.dld.2015.12.022 [Abstract AISF 2016].
    • (2016) DLD , vol.48
    • Di Maio, V.C.1    Cento, V.2    Di Paolo, D.3
  • 83
    • 84940942461 scopus 로고    scopus 로고
    • Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir
    • [83] Krishnan, P., Tripathi, R., Schnell, G., et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir. Antimicrobial Agents and Chemotherapy 59 (2015), 5445–5454.
    • (2015) Antimicrobial Agents and Chemotherapy , vol.59 , pp. 5445-5454
    • Krishnan, P.1    Tripathi, R.2    Schnell, G.3
  • 84
    • 84986568748 scopus 로고    scopus 로고
    • The emergence of NS5B Resistant associated variant S282T after Sofosbuvir-based treatment
    • [84] Gane, E.J., Abergel, A., Metivier, S., et al. The emergence of NS5B Resistant associated variant S282T after Sofosbuvir-based treatment. Hepatology, 62, 2015, S322A.
    • (2015) Hepatology , vol.62 , pp. S322A
    • Gane, E.J.1    Abergel, A.2    Metivier, S.3
  • 85
    • 84913603634 scopus 로고    scopus 로고
    • Retreatment of relapsers to Sofosbuvir/Ribavirin with Sofosbuvir/Ledipasvir: complete and rapid virologic suppression by week 4
    • [85] Osinusi, A., Marti, M., Townsend, K., et al. Retreatment of relapsers to Sofosbuvir/Ribavirin with Sofosbuvir/Ledipasvir: complete and rapid virologic suppression by week 4. Journal of Hepatology, 60, 2014, S56.
    • (2014) Journal of Hepatology , vol.60 , pp. S56
    • Osinusi, A.1    Marti, M.2    Townsend, K.3
  • 86
    • 84929600780 scopus 로고    scopus 로고
    • Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
    • [86] Wyles, D., Pockros, P., Morelli, G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 61 (2015), 1793–1797.
    • (2015) Hepatology , vol.61 , pp. 1793-1797
    • Wyles, D.1    Pockros, P.2    Morelli, G.3
  • 87
    • 84927798764 scopus 로고    scopus 로고
    • Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
    • [87] Lenz, O., Verbinnen, T., Fevery, B., et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Journal of Hepatology 62 (2015), 1008–1014.
    • (2015) Journal of Hepatology , vol.62 , pp. 1008-1014
    • Lenz, O.1    Verbinnen, T.2    Fevery, B.3
  • 88
    • 84957899900 scopus 로고    scopus 로고
    • Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with Paritaprevir-Ritonavir and Ombitasvir
    • [88] Krishnan, P., Schnell, G., Tripathi, R., et al. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrobial Agents and Chemotherapy 60 (2015), 1106–1113.
    • (2015) Antimicrobial Agents and Chemotherapy , vol.60 , pp. 1106-1113
    • Krishnan, P.1    Schnell, G.2    Tripathi, R.3
  • 89
    • 84939260843 scopus 로고    scopus 로고
    • Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: the C-Worthy study
    • [89] Black, S., Pak, I., Ingravallo, P., et al. Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: the C-Worthy study. Journal of Hepatology 62 (2015), S677–S678.
    • (2015) Journal of Hepatology , vol.62 , pp. S677-S678
    • Black, S.1    Pak, I.2    Ingravallo, P.3
  • 90
    • 85073892854 scopus 로고    scopus 로고
    • Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing
    • [90] Di Maio, V.C., Armenia, D., Bellocchi, M.C., et al. Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing. Journal of Hepatology, 62, 2015, S688.
    • (2015) Journal of Hepatology , vol.62 , pp. S688
    • Di Maio, V.C.1    Armenia, D.2    Bellocchi, M.C.3
  • 91
    • 84964762607 scopus 로고    scopus 로고
    • Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
    • [91] Dvory-Sobol, H., Wyles, D., Ouyang, W., et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. Journal of Hepatology, 62, 2015, S221.
    • (2015) Journal of Hepatology , vol.62 , pp. S221
    • Dvory-Sobol, H.1    Wyles, D.2    Ouyang, W.3
  • 92
    • 84876246624 scopus 로고    scopus 로고
    • Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir
    • [92] Wang, C., Sun, J.H., O'Boyle, D.R., et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrobial Agents and Chemotherapy 57 (2013), 2054–2065.
    • (2013) Antimicrobial Agents and Chemotherapy , vol.57 , pp. 2054-2065
    • Wang, C.1    Sun, J.H.2    O'Boyle, D.R.3
  • 93
    • 84896460675 scopus 로고    scopus 로고
    • Hepatitis C virus NS5A inhibitors and drug resistance mutations
    • [93] Nakamoto, S., Kanda, T., Wu, S., et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World Journal of Gastroenterology 20 (2014), 2902–2912.
    • (2014) World Journal of Gastroenterology , vol.20 , pp. 2902-2912
    • Nakamoto, S.1    Kanda, T.2    Wu, S.3
  • 94
    • 84939256727 scopus 로고    scopus 로고
    • Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
    • [94] Lawitz, E., Flamm, S., Yang, J.C., et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Journal of Hepatology, 62, 2015, S192.
    • (2015) Journal of Hepatology , vol.62 , pp. S192
    • Lawitz, E.1    Flamm, S.2    Yang, J.C.3
  • 95
    • 84968808058 scopus 로고    scopus 로고
    • Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor-containing regimen
    • [95] Hezode, C., Chevaliez, S., Scoazec, G., et al. Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor-containing regimen. Hepatology, 62(Suppl. 2), 2015, 763A.
    • (2015) Hepatology , vol.62 , pp. 763A
    • Hezode, C.1    Chevaliez, S.2    Scoazec, G.3
  • 96
    • 84950981068 scopus 로고    scopus 로고
    • Results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease
    • [96] Lawitz, E., Poordad, F., Gutierrez, J.A., et al. Results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease. Hepatology, 62(Suppl. 1), 2015, S227A.
    • (2015) Hepatology , vol.62 , pp. S227A
    • Lawitz, E.1    Poordad, F.2    Gutierrez, J.A.3
  • 97
    • 84979087007 scopus 로고    scopus 로고
    • Retreatment of HCV Genotype 1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir
    • [97] Poordad, F., Bennett, M., Sepe, T.E., et al. Retreatment of HCV Genotype 1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir. Hepatology, 62(Suppl. 1), 2015, 1392A.
    • (2015) Hepatology , vol.62 , pp. 1392A
    • Poordad, F.1    Bennett, M.2    Sepe, T.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.